Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
1995-12-15
|
pubmed:abstractText |
We introduced the gene for wild-type human p53 or p21, a critical downstream mediator of p53-induced growth suppression, into a p53-deficient mouse prostate cancer cell line using a recombinant adenoviral vector (Ad5CMV-p53 or Ad5CMV-p21). Elevated levels of endogenous mouse p21 mRNA provided evidence for the functional activity of virally transduced p53. Functional activity of viral-transduced p21 was demonstrated through immunoprecipitation of cellular protein extracts, which showed that the viral-transduced p21 associates with cyclin-dependent kinase 2 and was sufficient to down-regulate the activity of the cyclin-dependent kinase by approximately 65%. In vitro growth assays revealed significantly higher growth suppression after Ad5CMV-p21 infection compared to Ad5CMV-p53. In vivo studies in syngeneic male mice with established s.c. prostate tumors demonstrated that the rate of growth and final tumor volume were reduced to a much greater extent in mice that received intratumor injection of Ad5CMV-p21 compared to Ad5CMV-p53. In addition, the survival of host animals bearing tumors that were infected with Ad5CMV-p21, but not Ad5CMV-p53, was significantly extended. These data suggest that Ad5CMV-p21 may be effective as a therapeutic agent for prostate cancer.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cdkn1a protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclins,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
5151-5
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7585563-Adenoviridae,
pubmed-meshheading:7585563-Animals,
pubmed-meshheading:7585563-Cell Division,
pubmed-meshheading:7585563-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:7585563-Cyclins,
pubmed-meshheading:7585563-Gene Therapy,
pubmed-meshheading:7585563-Genes, p53,
pubmed-meshheading:7585563-Humans,
pubmed-meshheading:7585563-Male,
pubmed-meshheading:7585563-Mice,
pubmed-meshheading:7585563-Prostatic Neoplasms,
pubmed-meshheading:7585563-Protein Kinase Inhibitors,
pubmed-meshheading:7585563-Tumor Cells, Cultured
|
pubmed:year |
1995
|
pubmed:articleTitle |
In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.
|
pubmed:affiliation |
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|